Abstract
Purpose :
Establish efficacy of Micropulse laser (MPL) for IPCV Aflibercept resistant cases
<div class="grammarly-disable-indicator"> </div><div class="grammarly-disable-indicator"> </div>
Methods :
Six Eyes of six patients were diagnosed with IPCV based on Indocyanine Green Angiography were treated monthly with Aflibercept injections and were unresponsive. Unresponsive cases were defined as those with no change in VA or PED reduction in height after 3 monthly Aflibercept injections. Micropulse laser was focally applied for areas of PED or obvious leaking spot, parameters were customised according to individual variability. Eyes were examined at weeks 4, 8 and 12 after laser with concomitant Aflibercept injections
<div class="grammarly-disable-indicator"> </div><div class="grammarly-disable-indicator"> </div>
Results :
Five eyes showed positive changes after MPL, while one eye had no difference. There is a trend in the response, at week4 the PED is more in size, with increase in height as measured in microns on OCT, while it would reduce up to week 12 of our observation, difference is statistically significant when compared to aflibercept only eyes. Changes in visual acuity was not of any statisitical significance
<div class="grammarly-disable-indicator"> </div><div class="grammarly-disable-indicator"> </div>
Conclusions :
Micropulse laser treatments can be a safe augmentation with aflibercept injections to maximise response to treatment in cases of unresponsive IPCV. Further studies to be performed for generalizability.
<div class="grammarly-disable-indicator"> </div><div class="grammarly-disable-indicator"> </div>
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.